Author: Tom Wilemon
Oct. 4, 2018—Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.
Oct. 4, 2018—Singer Anita Cochran had famous friends in the room when she celebrated her last cancer treatment, but the person with her who mattered the most was her 89-year-old father.
Oct. 3, 2018—Using lesion network mapping, a recently developed technique for analyzing how the brain works, Ryan Darby, MD, assistant professor of Neurology at Vanderbilt, studied free will perception related to movement decisions.
Sep. 27, 2018—A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer, the third most common cancer among both men and women in the United States.
Sep. 27, 2018—A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.
Sep. 20, 2018—The T.J. Martell Foundation’s 6th Annual Chic Awearness fundraising event that supports ovarian cancer research at Vanderbilt-Ingram Cancer Center will be held Monday, Sept. 24, 6:30 – 8:30 p.m.
Sep. 20, 2018—The Centers for Disease Control and Prevention released new clinical recommendations for health care providers treating children with mild traumatic brain injury, often referred to as concussion.
Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
Aug. 30, 2018—A decade after taking part in the first clinical trial of deep brain stimulation (DBS) administered during very early-stage Parkinson’s disease, participants will return to Vanderbilt University Medical Center this year to be re-evaluated.